Department of Cell Biology, Key Laboratory of Cell Biology, Key Laboratory of Medical Cell Biology, Ministry of Education, Ministry of Public Health, China Medical University, Shenyang, 110122, PR China.
Mikrochim Acta. 2024 Apr 22;191(5):279. doi: 10.1007/s00604-024-06362-9.
The therapeutic effect of gefitinib on colorectal cancer (CRC) is unclear, but it has been reported that stromal cells in the tumor microenvironment may have an impact on drug sensitivity. Herein, we established a microfluidic co-culture system and explored the sensitivity of CRC cells co-cultured with cancer-associated fibroblasts (CAFs) to gefitinib. The system consisted of a multichannel chip and a Petri dish. The chambers in the chip and dish were designed to continuously supply nutrients for long-term cell survival and create chemokine gradients for driving cell invasion without any external equipment. Using this system, the proliferation and invasiveness of cells were simultaneously evaluated by quantifying the area of cells and the migration distance of cells. In addition, the system combined with live cell workstation could evaluate the dynamic drug response of co-cultured cells and track individual cell trajectories in real-time. When CRC cells were co-cultured with CAFs, CAFs promoted CRC cell proliferation and invasion and reduced the sensitivity of cells to gefitinib through the exosomes secreted by CAFs. Furthermore, the cells that migrated out of the chip were collected, and EMT-related markers were determined by immunofluorescent and western blot assays. The results demonstrated that CAFs affected the response of CRC cells to gefitinib by inducing EMT, providing new ideas for further research on the resistance mechanism of gefitinib. This suggests that targeting CAFs or exosomes might be a new approach to enhance CRC sensitivity to gefitinib, and our system could be a novel platform for investigating the crosstalk between tumor cells and CAFs and understanding multiple biological changes of the tumor cells in the tumor microenvironment.
吉非替尼对结直肠癌(CRC)的治疗效果尚不清楚,但据报道,肿瘤微环境中的基质细胞可能对药物敏感性有影响。在此,我们建立了一个微流控共培养系统,探索了与癌症相关成纤维细胞(CAFs)共培养的 CRC 细胞对吉非替尼的敏感性。该系统由多通道芯片和培养皿组成。芯片和培养皿中的腔室旨在为长期细胞存活提供持续的营养,并创建趋化因子梯度以驱动细胞侵袭,而无需任何外部设备。使用该系统,通过量化细胞面积和细胞迁移距离,同时评估细胞的增殖和侵袭能力。此外,该系统与活细胞工作站相结合,可评估共培养细胞的动态药物反应,并实时跟踪单个细胞轨迹。当 CRC 细胞与 CAFs 共培养时,CAFs 通过 CAFs 分泌的外泌体促进 CRC 细胞增殖和侵袭,并降低细胞对吉非替尼的敏感性。此外,从芯片中迁移出的细胞被收集,并通过免疫荧光和 Western blot 分析确定 EMT 相关标志物。结果表明,CAFs 通过诱导 EMT 影响 CRC 细胞对吉非替尼的反应,为进一步研究吉非替尼耐药机制提供了新的思路。这表明靶向 CAFs 或外泌体可能是增强 CRC 对吉非替尼敏感性的新方法,我们的系统可以成为研究肿瘤细胞与 CAFs 之间相互作用以及了解肿瘤微环境中肿瘤细胞多种生物学变化的新平台。